You are here

  • Home
  • Archive
  • Volume 82, Issue 5
  • Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by De Santis et al

Article info

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by De Santis et al

Authors

  • Sofia Ramiro Rheumatology, Zuyderland Medical Centre Heerlen, Heerlen, Limburg, The Netherlands Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands PubMed articlesGoogle scholar articles
  • Rémy L M Mostard Department of Pulmonology, Zuyderland Medical Centre Heerlen, Heerlen, The Netherlands PubMed articlesGoogle scholar articles
  • Robert B M Landewé Rheumatology, Zuyderland Medical Centre Heerlen, Heerlen, Limburg, The Netherlands Rheumatology & Clinical Immunology, Amsterdam Universitair Medische Centra, Duivendrecht, Noord-Holland, The Netherlands PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Sofia Ramiro, Rheumatology, Leiden University Medical Center, 2300 RC Leiden, Zuid-Holland, The Netherlands; sofiaramiro{at}gmail.com
View Full Text

Citation

Ramiro S, Mostard RLM, Landewé RBM
Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by De Santis et al
Annals of the Rheumatic Diseases 2023;82:e112.

Publication history

  • Received February 5, 2021
  • Accepted February 6, 2021
  • First published February 16, 2021.
Online issue publication 
October 18, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage